| [1] |
Syed-Abdul MM. 2023. Lipid metabolism in metabolic-associated steatotic liver disease (MASLD). |
| [2] |
Miao L, Targher G, Byrne CD, Cao YY, Zheng MH. 2024. Current status and future trends of the global burden of MASLD. |
| [3] |
Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, et al. 2023. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. |
| [4] |
Sandireddy R, Sakthivel S, Gupta P, Behari J, Tripathi M, et al. 2024. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. |
| [5] |
Le MH, Yeo YH, Zou B, Barnet S, Henry L, et al. 2022. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. |
| [6] |
Younossi ZM, Stepanova M, Ong J, Trimble G, AlQahtani S, et al. 2021. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. |
| [7] |
Hagström H, Shang Y, Hegmar H, Nasr P. 2024. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. |
| [8] |
Younossi ZM, Kalligeros M, Henry L. 2025. Epidemiology of metabolic dysfunction-associated steatotic liver disease. |
| [9] |
Stefan N, Yki-Järvinen H, Neuschwander-Tetri BA. 2025. Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. |
| [10] |
Nguyen M, Asgharpour A, Dixon DL, Sanyal AJ, Mehta A. 2024. Emerging therapies for MASLD and their impact on plasma lipids. |
| [11] |
Machado MV. 2023. MASLD treatment-a shift in the paradigm is imminent. |
| [12] |
Sylvers-Davie KL, Davies BSJ. 2021. Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8. |
| [13] |
Luo M, Peng D. 2018. ANGPTL8: an important regulator in metabolic disorders. |
| [14] |
Guo C, Wang C, Deng X, He J, Yang L, et al. 2021. ANGPTL8 in metabolic homeostasis: more friend than foe? |
| [15] |
Chen S, Feng M, Zhang S, Dong Z, Wang Y, et al. 2019. ANGPTL8 mediates food-driven resetting of hepatic circadian clock in mice. |
| [16] |
Petrescu M, Vlaicu SI, Ciumărnean L, Milaciu MV, Mărginean C, et al. 2022. Chronic inflammation-a link between nonalcoholic fatty liver disease (NAFLD) and dysfunctional adipose tissue. |
| [17] |
Zhang Y, Guo X, Yan W, Chen Y, Ke M, et al. 2017. ANGPTL8 negatively regulates NF-κB activation by facilitating selective autophagic degradation of IKKγ. |
| [18] |
Feng Y, Luo S, Fang C, Ma S, Fan D, et al. 2024. ANGPTL8 deficiency attenuates lipopolysaccharide-induced liver injury by improving lipid metabolic dysregulation. |
| [19] |
Su Y, Zhang R, Li K, Shen H, Nan M, et al. 2025. Angiopoietin-like protein 8 orchestrates macrophage glycogen metabolism and polarization via the JNK signaling pathway in cytokine storm syndrome. |
| [20] |
Li DP, Huang L, Kan RR, Meng XY, Wang SY, et al. 2023. LILRB2/PirB mediates macrophage recruitment in fibrogenesis of nonalcoholic steatohepatitis. |
| [21] |
Zhang Z, Yuan Y, Hu L, Tang J, Meng Z, et al. 2023. ANGPTL8 accelerates liver fibrosis mediated by HFD-induced inflammatory activity via LILRB2/ERK signaling pathways. |
| [22] |
Vatner DF, Goedeke L, Camporez JG, Lyu K, Nasiri AR, et al. 2018. ANGPTL8 antisense oligonucleotide improves adipose lipid metabolism and prevents diet-induced NAFLD and hepatic insulin resistance in rodents. |
| [23] |
Gusarova V, Banfi S, Alexa-Braun CA, Shihanian LM, Mintah IJ, et al. 2017. ANGPTL8 blockade with a monoclonal antibody promotes triglyceride clearance, energy expenditure, and weight loss in mice. |
| [24] |
Goyenvalle A, Jimenez-Mallebrera C, van Roon W, Sewing S, Krieg AM, et al. 2023. Considerations in the preclinical assessment of the safety of antisense oligonucleotides. |
| [25] |
Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. 2010. The safety and side effects of monoclonal antibodies. |
| [26] |
Li J, Lei HT, Cao L, Mi YN, Li S, et al. 2018. Crocin alleviates coronary atherosclerosis via inhibiting lipid synthesis and inducing M2 macrophage polarization. |
| [27] |
Chen S, Qian J, Shi X, Gao T, Liang T, et al. 2014. Control of hepatic gluconeogenesis by the promyelocytic leukemia zinc finger protein. |
| [28] |
Chen S, Li X, Liu L, Liu C, Han X. 2018. Ophiopogonin D alleviates high-fat diet-induced metabolic syndrome and changes the structure of gut microbiota in mice. |
| [29] |
Lu T, Chen F. 2012. Multiwfn: a multifunctional wavefunction analyzer. |
| [30] |
Lu T. 2024. A comprehensive electron wavefunction analysis toolbox for chemists, Multiwfn. |
| [31] |
Kimura S, Noda T, Yoshimori T. 2007. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. |
| [32] |
Shui G, Cheong WF, Jappar IA, Hoi A, Xue Y, et al. 2011. Derivatization-independent cholesterol analysis in crude lipid extracts by liquid chromatography/mass spectrometry: applications to a rabbit model for atherosclerosis. |
| [33] |
Ru J, Li P, Wang J, Zhou W, Li B, et al. 2014. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. |
| [34] |
Sherriff JL, O'Sullivan TA, Properzi C, Oddo JL, Adams LA. 2016. Choline, its potential role in nonalcoholic fatty liver disease, and the case for human and bacterial genes. |
| [35] |
Gaudet D, Gonciarz M, Shen X, Leohr JK, Beyer TP, et al. 2025. Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial. |
| [36] |
Tufail T, Ain HBU, Ikram A, Arshad MT, Abdullahi MA. 2025. Functional, nutraceutical and health endorsing perspectives of saffron. |
| [37] |
José Bagur M, Alonso Salinas GL, Jiménez-Monreal AM, Chaouqi S, Llorens S, et al. 2017. Saffron: an old medicinal plant and a potential novel functional food. |
| [38] |
Li T, Li Y, Chen J, Nan M, Zhou X, et al. 2025. Hyperibone J exerts antidepressant effects by targeting ADK to inhibit microglial P2X7R/TLR4-mediated neuroinflammation. |
| [39] |
Hassan M, Coutsias EA. 2021. Protein secondary structure motifs: a kinematic construction. |
| [40] |
Lamark T, Svenning S, Johansen T. 2017. Regulation of selective autophagy: the P62/SQSTM1 paradigm. |
| [41] |
Bastani S, Vahedian V, Rashidi M, Mir A, Mirzaei S, et al. 2022. An evaluation on potential anti-oxidant and anti-inflammatory effects of Crocin. |
| [42] |
Pourmousavi L, Asadi RH, Zehsaz F, Jadidi RP. 2024. Potential therapeutic effects of crocin. |
| [43] |
Nikbakht-Jam I, Khademi MM, Nosrati M, Eslami S, Foroutan-Tanha M, et al. 2016. Effect of crocin extracted from saffron on pro-oxidant–anti-oxidant balance in subjects with metabolic syndrome: a randomized, placebo-controlled clinical trial. |
| [44] |
Xie X, Xiao Q, Xiong Z, Yu C, Zhou J, et al. 2019. Crocin-I ameliorates the disruption of lipid metabolism and dysbiosis of the gut microbiota induced by chronic corticosterone in mice. |
| [45] |
Chin CF, LA Galam D, Gao L, Tan BC, Wong BH, et al. 2023. Blood-derived lysophospholipid sustains hepatic phospholipids and fat storage necessary for hepatoprotection in overnutrition. |
| [46] |
van der Veen JN, Kennelly JP, Wan S, Vance JE, Vance DE, et al. 2017. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. |
| [47] |
Jaafarinia A, Kafami B, Sahebnasagh A, Saghafi F. 2022. Evaluation of therapeutic effects of crocin in attenuating the progression of diabetic nephropathy: a preliminary randomized triple-blind placebo-controlled trial. |
| [48] |
Drygalski K. 2025. Pharmacological treatment of MASLD: contemporary treatment and future perspectives. |
| [49] |
Brisnovali NF, Haney C, Goedeke L. 2024. Rezdiffra™ (resmetirom): a THR-β agonist for non-alcoholic steatohepatitis. |
| [50] |
Zhang C, Wang J. 2025. Adverse events associated with obeticholic acid: a real-world, pharmacovigilance study. |